blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3384900

EP3384900 - STABLE DOSAGE FORM OF ETIDRONATE-CYTARABINE CONJUGATE [Right-click to bookmark this link]
Former [2018/41]STABLE DOSAGE FORM OF ETIDRONATE-CYTARABINE CONJUGATE, AND USE THEREOF
[2023/18]
StatusNo opposition filed within time limit
Status updated on  14.06.2024
Database last updated on 12.07.2024
FormerThe patent has been granted
Status updated on  07.07.2023
FormerGrant of patent is intended
Status updated on  12.04.2023
FormerExamination is in progress
Status updated on  15.01.2021
FormerRequest for examination was made
Status updated on  07.09.2018
FormerThe international publication has been made
Status updated on  15.06.2017
Most recent event   Tooltip05.07.2024Lapse of the patent in a contracting state
New state(s): MC		published on 07.08.2024 [2024/32]
Applicant(s)For all designated states
MAXWELL BIOTECH GROUP Ltd.
ul. Radischevskaya
Verkhnaya d. 12/19 str. 1
Moscow 109240 / RU
[2021/28]
Former [2018/41]For all designated states
Osteros Biomedica Ltd.
ul. Radischevskaya
Verkhnaya d.12/19 str.1
Moscow 109240 / RU
Inventor(s)01 / IVANOVA, Ekaterina Alekseevna
Fergansky pr-d d.3 korp.2 kv.43
Moscow 109507 / RU
02 / KARPEISKY, Alexander
20 Vernier Avenue
Lafayette Colorado 80026 / US
03 / ZINNEN, Shawn P.
2080 Grape Street
Denver Colorado 80207 / US
04 / CARALLI, Lisa Lynn
13921 Mercado Drive
Del Mar California 92014 / US
05 / SALURIALAM, Rina Diana
3633 Indiana Street Apt. 11
San Diego California 92103 / US
 [2018/41]
Representative(s)Glawe, Delfs, Moll
Partnerschaft mbB von
Patent- und Rechtsanwälten
Postfach 13 03 91
20103 Hamburg / DE
[2018/41]
Application number, filing date16871137.228.11.2016
[2018/41]
WO2016RU50076
Priority number, dateRU2015015145001.12.2015         Original published format: RU 2015151450
[2018/41]
Filing languageRU
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017095274
Date:08.06.2017
Language:RU
[2017/23]
Type: A1 Application with search report 
No.:EP3384900
Date:10.10.2018
Language:EN
[2018/41]
Type: B1 Patent specification 
No.:EP3384900
Date:09.08.2023
Language:EN
[2023/32]
Search report(s)International search report - published on:RU08.06.2017
(Supplementary) European search report - dispatched on:EP24.06.2019
ClassificationIPC:A61K9/19, A61K31/7068, A61K31/663, A61K47/02, A61P35/04
[2023/18]
CPC:
A61K9/19 (EP,IL,US); A61K9/0019 (IL,RU); A61K31/663 (EP,IL,RU,US);
A61K31/7068 (EP,IL,RU,US); A61K47/02 (EP,IL,RU,US); A61P35/00 (IL,RU);
A61P35/04 (EP,IL,US) (-)
C-Set:
A61K31/663, A61K2300/00 (EP,US);
A61K31/7068, A61K2300/00 (US,EP)
Former IPC [2019/30]A61K9/19, A61K31/7068, A61K31/663, A61K47/02, A61P35/00, A61P35/04
Former IPC [2018/41]A61K9/19, A61K31/7068, A61K31/663, A61K47/02, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/41]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:STABILE DOSIERUNGSFORM VON ETIDRONAT-CYTARABIN-KONJUGAT[2023/18]
English:STABLE DOSAGE FORM OF ETIDRONATE-CYTARABINE CONJUGATE[2023/18]
French:FORME GALÉNIQUE STABILISÉE D'UN CONJUGUÉ DE CYTARABINE ET D'ÉTIDRONATE[2023/18]
Former [2018/41]STABILE DOSIERUNGSFORM VON ETIDRONAT-CYTARABIN-KONJUGAT UND DEREN VERWENDUNG
Former [2018/41]STABLE DOSAGE FORM OF ETIDRONATE-CYTARABINE CONJUGATE, AND USE THEREOF
Former [2018/41]FORME GALÉNIQUE STABILISÉ D'UN CONJUGUÉ D'ÉTHYDRONATE AVEC LE CITRABINE ET SON UTILISATION
Entry into regional phase19.06.2018Translation filed 
19.06.2018National basic fee paid 
19.06.2018Search fee paid 
19.06.2018Designation fee(s) paid 
19.06.2018Examination fee paid 
Examination procedure19.06.2018Examination requested  [2018/41]
19.06.2018Date on which the examining division has become responsible
07.01.2020Amendment by applicant (claims and/or description)
15.01.2021Despatch of a communication from the examining division (Time limit: M04)
03.05.2021Reply to a communication from the examining division
13.04.2023Communication of intention to grant the patent
05.07.2023Fee for grant paid
05.07.2023Fee for publishing/printing paid
05.07.2023Receipt of the translation of the claim(s)
Opposition(s)13.05.2024No opposition filed within time limit [2024/29]
Fees paidRenewal fee
26.11.2018Renewal fee patent year 03
27.11.2019Renewal fee patent year 04
25.11.2020Renewal fee patent year 05
30.11.2021Renewal fee patent year 06
26.10.2022Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT09.08.2023
CZ09.08.2023
DK09.08.2023
EE09.08.2023
ES09.08.2023
FI09.08.2023
HR09.08.2023
IT09.08.2023
LT09.08.2023
LV09.08.2023
MC09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SK09.08.2023
SM09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
[2024/32]
Former [2024/26]AT09.08.2023
CZ09.08.2023
DK09.08.2023
EE09.08.2023
ES09.08.2023
FI09.08.2023
HR09.08.2023
IT09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SK09.08.2023
SM09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/23]AT09.08.2023
CZ09.08.2023
DK09.08.2023
EE09.08.2023
ES09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SK09.08.2023
SM09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/22]AT09.08.2023
CZ09.08.2023
DK09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SM09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/20]AT09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RS09.08.2023
SE09.08.2023
SM09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/10]AT09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RS09.08.2023
SE09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/09]AT09.08.2023
FI09.08.2023
LT09.08.2023
NL09.08.2023
SE09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
Former [2024/08]LT09.08.2023
NL09.08.2023
NO09.11.2023
GR10.11.2023
Documents cited:Search[Y]WO2007021881  (SYNTA PHARMACEUTICALS CORP [US], et al);
 [Y]US2014051625  (KARPEISKY ALEXANDER [US], et al);
International search[Y]US6383999  (COYLE LAURIE ANN [US], et al);
 [Y]US2003175313  (GARREC DOROTHEE LE [CA], et al);
 [Y]US2010160208  (SCHLINGENSIEPEN KARL-HERMANN [DE], et al);
 [A]US2013184447  (PICCARIELLO THOMAS [US]);
 [Y]US2015165027  (IKEDA MEGUMI [JP], et al);
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.